Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
Published in Oncology

Journal Scan / Research · May 06, 2024

Nivolumab Plus Cabozantinib vs Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma

ESMO Open

 

 Save  Recommend
 Share

Additional Info

ESMO Open
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
ESMO Open 2024 Apr 19;9(5)102994, T Powles, M Burotto, B Escudier, AB Apolo, MT Bourlon, AY Shah, C Suárez, C Porta, CH Barrios, M Richardet, H Gurney, ER Kessler, Y Tomita, J Bedke, S George, C Scheffold, P Wang, V Fedorov, RJ Motzer, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated